We are live on ! Find out more
SLN icon

Silence Therapeutics

3 hedge funds and large institutions have $10.2M invested in Silence Therapeutics in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding

Funds holding: 2 → 3 (+1)

0% more ownership

Funds ownership: 1.81% → 1.81% (+0%)

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$1.67K

Top Sellers

No sellers this quarter

SLN Hedge Fund Activity: Q4 2020 in Review

3 of the 5,680 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q4 2020, worth a combined $10.2M — up 26% from $8.14M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new SLN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $1.67K.

  • 3 institutional investors held Silence Therapeutics (SLN) as of Q4 2020, up from 2 in Q3 2020.
  • Funds reported $10.2M of Silence Therapeutics stock for Q4 2020, up 26% quarter-over-quarter.
  • 1 fund opened new Silence Therapeutics positions in Q4 2020 and 0 closed out, a net change of +1 holder.
  • The largest Silence Therapeutics buyer in Q4 2020 was UBS Group, an estimated $1.67K added.

Based on aggregated 13F filings for Q4 2020.